FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Leonardo Ferrari

Research Profile

Disorders

Chemicals & Drugs

Procedures

Antineoplastic Combined Chemotherapy Protocols

Physiology

Postmenopause

Concepts & Ideas

Co-author Network

Publications

TOP 3
Emilio Bajetta; laura catena; Giuseppe Procopio; Sara De Dosso; Ettore Bichisao; Leonardo Ferrari; Antonia Martinetti; Marco Platania; Elena Verzoni; Barbara Formisano; Roberto Bajetta
Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
Emilio Bajetta; Giuseppe Procopio; laura catena; Antonia Martinetti; Sara De Dosso; Sergio Ricci; Alberto S Lecchi; Paolo F Boscani; Stefano Iacobelli; Giacomo Carteni; Filippo de Braud; Paola Loli; Andreas Tartaglia; Roberto Bajetta; Leonardo Ferrari
Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study.
Leonardo Ferrari; Silvia Della Torre; Paola Collini; Antonia Martinetti; Giuseppe Procopio; Sara De Dosso; Roberto Bajetta; laura catena
Kit protein (CD117) and proliferation index (Ki-67) evaluation in well and poorly differentiated neuroendocrine tumors.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Leonardo Ferrari (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Emilio Bajetta; laura catena; Giuseppe Procopio; Sara De Dosso; Ettore Bichisao; Leonardo Ferrari; Antonia Martinetti; Marco Platania; Elena Verzoni; Barbara Formisano; Roberto Bajetta
Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
Cancer chemotherapy and pharmacology 2007;59(5):637-42.
2006: Emilio Bajetta; Giuseppe Procopio; laura catena; Antonia Martinetti; Sara De Dosso; Sergio Ricci; Alberto S Lecchi; Paolo F Boscani; Stefano Iacobelli; Giacomo Carteni; Filippo de Braud; Paola Loli; Andreas Tartaglia; Roberto Bajetta; Leonardo Ferrari
Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study.
Cancer 2006;107(10):2474-81.
2006: Leonardo Ferrari; Silvia Della Torre; Paola Collini; Antonia Martinetti; Giuseppe Procopio; Sara De Dosso; Roberto Bajetta; laura catena
Kit protein (CD117) and proliferation index (Ki-67) evaluation in well and poorly differentiated neuroendocrine tumors.
Tumori 2006;92(6):531-5.
2006: Giuseppe Procopio; Riccardo Ricotta; Alberto Fusi; Luigi Celio; Sara De Dosso; laura catena; Leonardo Ferrari; Pasquale Quattrone; Elena Verzoni; Emilio Bajetta
Neuroendocrine tumors of the larynx: a clinical report and literature review.
Tumori 2006;92(1):72-5.
2005: Marco Maccauro; Carlo Villano; Gianluca Aliberti; Leonardo Ferrari; Maria Rita Castellani; Roberto Patuzzo; D Tshering; mario santinami; Emilio Bombardieri
Lymphoscintigraphy with intraoperative gamma probe sentinel node detection: clinical impact in patients with head and neck melanomas.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology 2005;49(3):245-51.
2005: Emilio Bajetta; laura catena; Giuseppe Procopio; Ettore Bichisao; Leonardo Ferrari; Silvia Della Torre; Sara De Dosso; S Iacobelli; Roberto Buzzoni; Luigi Mariani; J Rosai
Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(8):1374-80.
2004: Antonia Martinetti; Emilio Bajetta; Leonardo Ferrari; Nicoletta Zilembo; Ettore Seregni; M Del Vecchio; Raffaella Longarini; Ignazia La Torre; Luisa Toffolatti; D Paleari; Emilio Bombardieri
Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole.
Endocrine-related cancer 2004;11(4):771-9.
2004: Alberto Fusi; Giuseppe Procopio; Silvia Della Torre; Riccardo Ricotta; Gianpaolo Bianchini; Roberto Salvioni; Leonardo Ferrari; Antonia Martinetti; Giordano Savelli; Sergio Villa; Emilio Bajetta
Treatment options in hormone-refractory metastatic prostate carcinoma.
Tumori 2004;90(6):535-46.
2004: Leonardo Ferrari; Ettore Seregni; giovanni lucignani; Emilio Bajetta; Antonia Martinetti; Gianluca Aliberti; Federica Pallotti; Giuseppe Procopio; Silvia Della Torre; R Luksch; Emilio Bombardieri
Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors.
The International journal of biological markers 2004;19(4):295-304.
2004: Erminia Ferrario; Leonardo Ferrari; Paolo Bidoli; Daniela De Candis; Michele Del Vecchio; Sara De Dosso; Roberto Buzzoni; Emilio Bajetta
Treatment of cancer-related anemia with epoetin alfa: a review.
Cancer treatment reviews 2004;30(6):563-75.
2004: Leonardo Ferrari; Ettore Seregni; Gianluca Aliberti; Antonia Martinetti; Federica Pallotti; Carlo Villano; giovanni lucignani; Emilio Bombardieri
Comparative evaluation of two methods to assay thyroglobulin serum concentrations in patients with differentiated thyroid carcinomas.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology 2004;48(3):237-42.
2003: Emilio Bajetta; Giuseppe Procopio; Leonardo Ferrari; laura catena; Michele Del Vecchio; Emilio Bombardieri
Update on the treatment of neuroendocrine tumors.
Expert review of anticancer therapy 2003;3(5):631-42.
2003: Emilio Bajetta; Luigi Celio; Roberto Buzzoni; Leonardo Ferrari; Alfonso Marchianò; Antonia Martinetti; Raffaella Longarini; C Becerra; C Ilardi; W John
Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(10):1543-8.
2003: Antonia Martinetti; Ettore Seregni; Leonardo Ferrari; Federica Pallotti; Gianluca Aliberti; Angela Coliva; Silvia Fracassi; Emilio Bombardieri
Evaluation of circulating calcitonin: analytical aspects.
Tumori 2003;89(5):566-8.
2003: Ettore Seregni; Federica Pallotti; Franco Mattavelli; Leonardo Ferrari; Antonia Martinetti; Gianluca Aliberti; Carlo Villano; Maria Rita Castellani; Emilio Bombardieri
Diagnostic procedures in the follow-up of patients affected by MEN type 2.
Tumori 2003;89(5):563-5.
2003: Federica Pallotti; Ettore Seregni; Leonardo Ferrari; Antonia Martinetti; Donatella Biancolini; Emilio Bombardieri
Diagnostic and therapeutic aspects of iatrogenic hypoparathyroidism.
Tumori 2003;89(5):547-9.
2003: Leonardo Ferrari; Donatella Biancolini; Ettore Seregni; Gianluca Aliberti; Antonia Martinetti; Carlo Villano; Federica Pallotti; Carlo Chiesa; Emilio Bombardieri
Critical aspects of immunoradiometric thyroglobulin assays.
Tumori 2003;89(5):537-9.
2003: Luca Gattinoni; Massimiliano Alù; Leonardo Ferrari; Paola Nova; Michele Del Vecchio; Giuseppe Procopio; Agata Laudani; Biagio Agostara; Emilio Bajetta
Renal cancer treatment: a review of the literature.
Tumori 2003;89(5):476-84.
2003: Antonia Martinetti; Nicoletta Zilembo; Leonardo Ferrari; Giorgio Massimini; Anna Polli; Ignazia La Torre; riccardo giovanazzi; Paola Pozzi; Paolo Bidoli; Daniela De Candis; Ettore Seregni; Emilio Bombardieri; Emilio Bajetta
Bone turnover markers and insulin-like growth factor components in metastatic breast cancer: results from a randomised trial of exemestane vs megestrol acetate.
Anticancer research 2003;23(4):3485-91.
2003: Leonardo Ferrari; Emilio Bajetta; Antonia Martinetti; Luigi Celio; Raffaella Longarini; Ignazia La Torre; Roberto Buzzoni; Luca Gattinoni; Ettore Seregni; Emilio Bombardieri
Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole?
International journal of oncology 2003;22(5):1081-9.
2003: Silvia Della Torre; Giuseppe Procopio; Alberto Fusi; laura catena; Leonardo Ferrari; Paola Nova; Angela Denaro; Ettore Bichisao; Emilio Bajetta
Current treatments of neuroendocrine tumors role of biotherapy and chemotherapy.
Tumori 2003;89(2):111-6.
2002: Antonia Martinetti; Ettore Seregni; C Ripamonti; Leonardo Ferrari; F De Conno; Rosalba Miceli; Federica Pallotti; Angela Coliva; Donatella Biancolini; Emilio Bombardieri
Serum levels of tartrate-resistant acid phosphatase-5b in breast cancer patients treated with pamidronate.
The International journal of biological markers 2002;17(4):253-8.
2002: Nicoletta Zilembo; Luigi Mariani; Antonia Martinetti; Rosalba Miceli; Ettore Seregni; Ettore Bichisao; Ignazia La Torre; Paola Pozzi; Leonardo Ferrari; Daniela De Candis; V R Longarini; Emilio Bajetta; Emilio Bombardieri
c-erbB 2 serum level as prognostic factor in hormonally treated advanced breast cancer patients.
Breast (Edinburgh, Scotland) 2002;11(4):286-94.
2002: Emilio Bajetta; Antonia Martinetti; Nicoletta Zilembo; Paola Pozzi; Ignazia La Torre; Leonardo Ferrari; Ettore Seregni; Raffaella Longarini; G Salvucci; Emilio Bombardieri
Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(7):1059-66.
2002: Emilio Bajetta; Leonardo Ferrari; Giuseppe Procopio; laura catena; Erminia Ferrario; Antonia Martinetti; Maria Di Bartolomeo; Roberto Buzzoni; Luigi Celio; Milena Vitali; Elena Beretta; Ettore Seregni; Emilio Bombardieri
Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(4):614-21.
2002: Leonardo Ferrari; Antonia Martinetti; Nicoletta Zilembo; Paola Pozzi; Roberto Buzzoni; Ignazia La Torre; Luca Gattinoni; laura catena; Milena Vitali; Luigi Celio; Ettore Seregni; Emilio Bombardieri; Emilio Bajetta
Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients.
The Journal of steroid biochemistry and molecular biology 2002;80(4-5):411-8.
2002: Emilio Bajetta; Giuseppe Procopio; Leonardo Ferrari; Antonia Martinetti; Nicoletta Zilembo; laura catena; Massimiliano Alú; Torre Silvia Della; Daniele Alberti; Roberto Buzzoni
A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma.
Cancer 2002;94(2):299-304.
2001: Antonio Cassata; G Procoplo; M Alù; Leonardo Ferrari; Erminia Ferrario; Elena Beretta; R Longarini; G Busto; Daniela De Candis; Emilio Bajetta
Capecitabine: indications and future perspectives in the treatment of metastatic colorectal and breast cancer.
Tumori 2001;87(6):364-71.
2001: Emilio Bajetta; Giuseppe Procopio; Roberto Buzzoni; laura catena; Leonardo Ferrari; Michele Del Vecchio
Advances in diagnosis and therapy of neuroendocrine tumors.
Expert review of anticancer therapy 2001;1(3):371-81.
2001: Emilio Bajetta; Michele Del Vecchio; Milena Vitali; Antonia Martinetti; Leonardo Ferrari; Paola Queirolo; Mario Roberto Sertoli; T Cainelli; R Cellerino; Natale Cascinelli
A feasibility study using polychemotherapy (cisplatin + vindesine + dacarbazine) plus interferon-alpha or monochemotherapy with dacarbazine plus interferon-alpha in metastatic melanoma.
Tumori 2001;87(4):219-22.
2001: Ettore Seregni; Leonardo Ferrari; Emilio Bajetta; Antonia Martinetti; Emilio Bombardieri
Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12 Suppl 2():S69-72.
2000: Antonia Martinetti; Leonardo Ferrari; Luigi Celio; Luigi Mariani; Rosalba Miceli; Nicoletta Zilembo; Maria Di Bartolomeo; Luisa Toffolatti; Paola Pozzi; Ettore Seregni; Emilio Bombardieri; Emilio Bajetta
The luteinising hormone-releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers.
The Journal of steroid biochemistry and molecular biology 2000;75(1):65-73.
2000: Emilio Bajetta; Nicoletta Zilembo; Ettore Bichisao; Antonia Martinetti; Roberto Buzzoni; Paola Pozzi; Paolo Bidoli; Leonardo Ferrari; Luigi Celio
Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(8):1017-22.
2000: Emilio Bajetta; Ettore Bichisao; Salvatore Artale; Luigi Celio; Leonardo Ferrari; Maria Di Bartolomeo; Nicoletta Zilembo; Simonetta Chiara Stani; Roberto Buzzoni
New clinical trials for the treatment of neuroendocrine tumors.
The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR) 2000;44(1):96-101.
2000: Ettore Seregni; Leonardo Ferrari; M Stivanello; Luigi Dogliotti
Laboratory tests for neuroendocrine tumours.
The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR) 2000;44(1):22-41.
1999: Maria Grazia Daidone; Silvia Veneroni; E Benini; Gorana Tomasic; Danila Coradini; M Mastore; C Brambilla; Leonardo Ferrari; R Silvestrini
Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer.
International journal of cancer. Journal international du cancer 1999;84(6):580-6.
1999: Arturo Chiti; BJ Van Graafeiland; Giordano Savelli; Leonardo Ferrari; Ettore Seregni; Maria Rita Castellani; Emilio Bombardieri
Imaging of neuroendocrine gastro-entero-pancreatic tumours using radiolabelled somatostatin analogues.
Italian journal of gastroenterology and hepatology 1999;31 Suppl 2():S190-4.
1999: Emilio Bajetta; Leonardo Ferrari; Antonia Martinetti; Luigi Celio; Giuseppe Procopio; Salvatore Artale; Nicoletta Zilembo; Maria Di Bartolomeo; Ettore Seregni; Emilio Bombardieri
Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors.
Cancer 1999;86(5):858-65.
1999: Leonardo Ferrari; Ettore Seregni; Emilio Bajetta; Antonia Martinetti; Emilio Bombardieri
The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours.
Anticancer research 1999;19(4C):3415-27.
1999: Luigi Celio; Antonia Martinetti; Leonardo Ferrari; Roberto Buzzoni; Luigi Mariani; Rosalba Miceli; Ettore Seregni; Giuseppe Procopio; Antonio Cassata; Emilio Bombardieri; Emilio Bajetta
Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study.
Anticancer research 1999;19(3B):2261-8.
1999: Ettore Seregni; C Botti; E Bajetta; Leonardo Ferrari; Antonia Martinetti; S Nerini-Molteni; Emilio Bombardieri
Hormonal regulation of MUC1 expression.
The International journal of biological markers 1999;14(1):29-35.
1999: SN Molteni; Ettore Seregni; C Botti; Antonia Martinetti; Leonardo Ferrari; Flavio Crippa; Emilio Bombardieri
The breast cancer cell line MCF7 as a model of 99mTc-SestaMIBI, 99mTc-tetrofosmin and 99mTc-Medronate incorporation.
Anticancer research 1999;19(1A):255-9.
1998: Emilio Bajetta; Lorenza Rimassa; Carlo Carnaghi; Ettore Seregni; Leonardo Ferrari; Maria Di Bartolomeo; Enrico Regalia; Antonio Cassata; Giuseppe Procopio; Luigi Mariani
5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors.
Cancer 1998;83(2):372-8.
1998: C Botti; Ettore Seregni; Leonardo Ferrari; Antonia Martinetti; Emilio Bombardieri
Immunosuppressive factors: role in cancer development and progression.
The International journal of biological markers 1998;13(2):51-69.
1998: Emilio Bajetta; Luigi Celio; A Di Leo; Cesare Bartoli; S Pilotti; M Leutner; Aldo Bono; Leonardo Ferrari; Roberto Buzzoni; Nicoletta Zilembo; Daniela De Candis; Daniele Moglia
Effects of short-term pre-operative tamoxifen on steroid receptor and Ki-67 expression in primary breast cancer: an immunocytochemical study.
International journal of oncology 1998;12(4):853-8.
1998: Leonardo Ferrari; Ettore Seregni; Antonia Martinetti; BJ Van Graafeiland; S Nerini-Molteni; C Botti; Salvatore Artale; S Cresta; Emilio Bombardieri
Chromogranin A measurement in neuroendocrine tumors.
The International journal of biological markers 1998;13(1):3-9.
1998: S Massaron; Ettore Seregni; R Luksch; Michela Casanova; C Botti; Leonardo Ferrari; Antonia Martinetti; SN Molteni; Franca Fossati Bellani; Emilio Bombardieri
Neuron-specific enolase evaluation in patients with neuroblastoma.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1998;19(4):261-8.
1998: Emilio Bombardieri; Ettore Seregni; Maria Grazia Daidone; E Benini; S Massaron; Leonardo Ferrari; Giovanni Di Fronzo; R Silvestrini
P53 accumulation in primary breast cancer: a comparison between immunohistochemistry and a novel luminometric immunoassay.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1998;19(1):12-8.
1997: Emilio Bajetta; Leonardo Ferrari; Luigi Celio; Luigi Mariani; Rosalba Miceli; A Di Leo; Nicoletta Zilembo; Roberto Buzzoni; I Spagnoli; Antonia Martinetti; Ettore Bichisao; Ettore Seregni
The aromatase inhibitor letrozole in advanced breast cancer: effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels.
The Journal of steroid biochemistry and molecular biology 1997;63(4-6):261-7.
1997: C Botti; Ettore Seregni; S Mattioli; Antonia Martinetti; Leonardo Ferrari; Emilio Bombardieri
Bladder cancer monitoring using two novel urinary markers.
The International journal of biological markers 1997;12(4):174-80.
1997: C Botti; Antonia Martinetti; S Nerini-Molteni; Leonardo Ferrari
Anti-malignin antibody evaluation: a possible challenge for cancer management.
The International journal of biological markers 1997;12(4):141-7.
1997: Antonia Martinetti; Ettore Seregni; Emilio Bajetta; G F Bolelli; Leonardo Ferrari; S Massaron; C Botti; Emilio Bombardieri
Development of a rapid and ultrasensitive RIA method for estrogen (E2, E1, E1-S) determination with selective solid phase extraction.
The International journal of biological markers 1997;12(3):102-5.
1997: Emilio Bajetta; Nicoletta Zilembo; S Barni; C Noberasco; Antonia Martinetti; Leonardo Ferrari; Giuseppe Schieppati; Roberto Buzzoni; A Jirillo; M Amichetti; M D'Aprile; Giuseppe Comella; Ettore Bichisao; G F Bolelli; A Attili; Emilio Bombardieri
A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(7):649-54.
1997: Emilio Bajetta; Nicoletta Zilembo; C Noberasco; Antonia Martinetti; Luigi Mariani; Leonardo Ferrari; Roberto Buzzoni; M Greco; Cesare Bartoli; I Spagnoli; GM Danesini; Salvatore Artale; J Paolini
The minimal effective exemestane dose for endocrine activity in advanced breast cancer.
European journal of cancer (Oxford, England : 1990) 1997;33(4):587-91.
1997: Ettore Seregni; C Botti; S Massaron; Antonia Martinetti; Leonardo Ferrari; SN Molteni; Emilio Bombardieri
Mucinous markers in breast cancer.
Tumori 1997;83(2):550-1.
1997: Antonia Martinetti; Emilio Bajetta; Ettore Seregni; Nicoletta Zilembo; Leonardo Ferrari; C Noberasco; S Massaron; Lorenza Rimassa; Emilio Bombardieri
Serum markers of bone metastases in postmenopausal breast cancer patients treated with formestane.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1997;18(4):197-205.
1997: C Botti; Ettore Seregni; Sylvie Menard; Elda Tagliabue; A Bonanate; D Cantarella; C Lombardo; S Massaron; Antonia Martinetti; Leonardo Ferrari; Cristina Ghirelli; Piera Aiello; Emilio Bombardieri
Production of a novel monoclonal antibody against MUC4 mucin.
The International journal of biological markers 1997;12(1):42-3.
1996: A Di Leo; Emilio Bajetta; Leonardo Ferrari; L Biganzoli; Luigi Mariani; Carlo Carnaghi; E Camerini; Roberto Buzzoni; J M Ruiz
A dose-finding study of lanreotide (a somatostatin analog) in patients with colorectal carcinoma.
Cancer 1996;78(1):35-42.
1996: Monica Terenziani; Romano Demicheli; C Brambilla; Leonardo Ferrari; Angela Moliterni; Milvia Zambetti; A Caraceni; C Martini; Gianni Bonadonna
Vinorelbine: an active, non cross-resistant drug in advanced breast cancer. Results from a phase II study.
Breast cancer research and treatment 1996;39(3):285-91.
1996: Emilio Bajetta; Carlo Carnaghi; Leonardo Ferrari; I Spagnoli; Vincenzo Mazzaferro; Roberto Buzzoni
The role of somatostatin analogues in the treatment of gastro-enteropancreatic endocrine tumours.
Digestion 1996;57 Suppl 1():72-6.
1995: A Di Leo; Leonardo Ferrari; Emilio Bajetta; Cesare Bartoli; G Vicario; Daniele Moglia; Rosalba Miceli; M Callegari; Aldo Bono
Biological and clinical evaluation of lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer. A pilot study by the I.T.M.O. Group. Italian Trials in Medical Oncology.
Breast cancer research and treatment 1995;34(3):237-44.
1995: Maria Grazia Daidone; R Silvestrini; A Luisi; M Mastore; E Benini; Silvia Veneroni; C Brambilla; Leonardo Ferrari; M Greco; S Andreola
Changes in biological markers after primary chemotherapy for breast cancers.
International journal of cancer. Journal international du cancer 1995;61(3):301-5.
1994: Nicoletta Zilembo; Roberto Buzzoni; Luigi Celio; Cristina Noberasco; Leonardo Ferrari; A Laffranchi; G Vicario; S Dolci; Emilio Bajetta
Formestane as treatment of advanced breast cancer in elderly women.
Tumori 1994;80(6):433-7.
1994: A Di Leo; Emilio Bajetta; Franco Nolè; L Biganzoli; Leonardo Ferrari; Saro Oriana; G Riboldi; S Bohm; G Spatti; Francesco Raspagliesi
The intramuscular administration of granulocyte colony-stimulating factor as an adjunct to chemotherapy in pretreated ovarian cancer patients: an Italian Trials in Medical Oncology (ITMO) Group pilot study.
British journal of cancer 1994;69(5):961-6.
1994: Emilio Bajetta; Luigi Celio; Nicoletta Zilembo; Aldo Bono; D Galluzzo; Maria Giulia Zampino; A Longhi; Leonardo Ferrari; Roberto Buzzoni
Ovarian function suppression with the gonadotrophin-releasing hormone (GnRH) analogue goserelin in premenopausal advanced breast cancer.
Tumori 1994;80(1):28-32.
1994: Leonardo Ferrari; Nicoletta Zilembo; Emilio Bajetta; Roberto Buzzoni; Cristina Noberasco; Antonia Martinetti; Luigi Celio; E Galante; S Orefice; Annamaria Cerrotta
Effect of two-4-hydroxyandrostenedione doses on serum insulin-like growth factor I levels in advanced breast cancer.
Breast cancer research and treatment 1994;30(2):127-32.
1994: Emilio Bajetta; Nicoletta Zilembo; Roberto Buzzoni; Cristina Noberasco; Antonia Martinetti; Leonardo Ferrari; Cesare Bartoli; Virgilio Sacchini; A Attili; P Lepera
Formestane: effective therapy in postmenopausal women with advanced breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5 Suppl 7():S15-7.
1993: P Ballerini; Saro Oriana; Piergiorgio DUCA; Antonia Martinetti; E Venturelli; Leonardo Ferrari; S Dolci; G Secreto
Urinary testosterone as a marker of risk of recurrence in operable breast cancer.
Breast cancer research and treatment 1993;26(1):1-6.
1992: P Ballerini; L Callegari; I Del Prato; Daniele Moglia; Annamaria Cerrotta; L Adorni; Leonardo Ferrari; G Secreto
Cationic content in multiple mammary cysts.
Tumori 1992;78(3):198-9.
1991: Gianni Bonadonna; Pinuccia Valagussa; C Brambilla; Angela Moliterni; Milvia Zambetti; Leonardo Ferrari
Adjuvant and neoadjuvant treatment of breast cancer with chemotherapy and/or endocrine therapy.
Seminars in oncology 1991;18(6):515-24.
1991: Angela Moliterni; Gianni Bonadonna; Pinuccia Valagussa; Leonardo Ferrari; Milvia Zambetti
Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(7):1124-30.
1990: Gianni Bonadonna; U Veronesi; C Brambilla; Leonardo Ferrari; A Luini; Marco Greco; C Bartoli; G Coopmans de Yoldi; Roberto Zucali; F Rilke
Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more.
Journal of the National Cancer Institute 1990;82(19):1539-45.
1989: C Brambilla; Milvia Zambetti; Leonardo Ferrari; Gianni Bonadonna
Mitomycin C and vinblastine in advanced refractory breast cancer.
Tumori 1989;75(2):141-4.
1987: Leonardo Ferrari; Emilio Bajetta; Luca Gianni; C Verusio; C Bartoli; Pinuccia Valagussa; Gianni Bonadonna
Four-drug sequential regimen in advanced breast cancer.
Breast cancer research and treatment 1987;10(2):151-7.